Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropidoxuridine and WBRT in Brain Metastases
NCT02993146Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2017
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropidoxuridine in brain metastases, sponsored by National Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 8 weeks. Started May 2017; status: active, not recruiting.
02
Drugs
ropidoxuridine
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT02993146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993146.